Literature DB >> 16127090

Galactomannan in piperacillin-tazobactam: how much and to what extent?

Marco Machetti, Elisa Furfaro, Claudio Viscoli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16127090      PMCID： PMC1195433          DOI： 10.1128/AAC.49.9.3984-3985.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  10 in total

1.  Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.

Authors:  J Maertens; J Verhaegen; K Lagrou; J Van Eldere; M Boogaerts
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

2.  False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam.

Authors:  Annie Sulahian; Sophie Touratier; Patricia Ribaud
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

3.  Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies.

Authors:  Olivier Adam; Anne Aupérin; Fanny Wilquin; Jean-Henri Bourhis; Bertrand Gachot; Elisabeth Chachaty
Journal:  Clin Infect Dis       Date:  2004-02-27       Impact factor: 9.079

4.  Lack of evidence that false-positive Aspergillus galactomannan antigen test results are due to treatment with piperacillin-tazobactam.

Authors:  Olaf Penack; Stefan Schwartz; Eckhard Thiel; Igor Wolfgang Blau
Journal:  Clin Infect Dis       Date:  2004-11-01       Impact factor: 9.079

5.  Methodological issues in assessing reproducibility--a comparative study of various indices of reproducibility applied to repeat ELISA serologic tests for Lyme disease.

Authors:  M C Tammemagi; J W Frank; M Leblanc; H Artsob; D L Streiner
Journal:  J Clin Epidemiol       Date:  1995-09       Impact factor: 6.437

6.  A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis.

Authors:  D Stynen; A Goris; J Sarfati; J P Latgé
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

7.  Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus.

Authors:  J P Latgé; H Kobayashi; J P Debeaupuis; M Diaquin; J Sarfati; J M Wieruszeski; E Parra; J P Bouchara; B Fournet
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

8.  Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction.

Authors:  Thomas J Walsh; Shmuel Shoham; Ruta Petraitiene; Tin Sein; Robert Schaufele; Amy Kelaher; Heidi Murray; Christine Mya-San; John Bacher; Vidmantas Petraitis
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

9.  False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam.

Authors:  Claudio Viscoli; Marco Machetti; Paola Cappellano; Barbara Bucci; Paolo Bruzzi; Maria Teresa Van Lint; Andrea Bacigalupo
Journal:  Clin Infect Dis       Date:  2004-02-27       Impact factor: 9.079

10.  Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum.

Authors:  Nina Singh; Asia Obman; Shahid Husain; Sherrie Aspinall; Sue Mietzner; Janet E Stout
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191
  10 in total
  5 in total

1.  Generic piperacillin/tazobactam is not associated with galactomannan false-positivity in adult patients with cancer: a case-control study.

Authors:  J-H Ko; K R Peck; W J Lee; J Y Lee; S Y Cho; Y E Ha; C-I Kang; D R Chung; C W Jung; E-S Kang; J-H Song
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-17       Impact factor: 3.267

Review 2.  Fungal infections of the CNS: treatment strategies for the immunocompromised patient.

Authors:  Katharine E Black; Lindsey R Baden
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  Reactivity of (1-->3)-beta-d-glucan assay with commonly used intravenous antimicrobials.

Authors:  Francisco M Marty; Colleen M Lowry; Steven J Lempitski; David W Kubiak; Malcolm A Finkelman; Lindsey R Baden
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

4.  A comparison of galactomannan-ELISA and a newly developed galactomannan-LATEX test in the serologic diagnosis of invasive aspergillosis in patients with hematologic malignancies.

Authors:  X Keutgen; R Hachem; Y Jiang; T Pham-Williams; J Tarrand; I Raad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07-11       Impact factor: 3.267

5.  Early Diagnosis of Invasive Aspergillosis in Neutropenic Patients. Comparison between Serum Galactomannan and Polymerase Chain Reaction.

Authors:  Rodrigo Lopes da Silva; Patrícia Ribeiro; Natacha Abreu; Teresa Ferreira; Teresa Fernandes; Alexandra Monteiro; Fátima Costa; Joana Caldas; Madalena Silva; Luísa Carande; Gilda Ferreira; António Conduto; Ernesto Cruz; Maria Henrique Sousa; António Silva Rodrigues; Isabel Costa; Joana Veiga; Aida Botelho de Sousa
Journal:  Clin Med Insights Oncol       Date:  2010-07-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.